In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Real-World Outcomes Using a Novel Directional Lead from a Deep Brain Stimulation (DBS) Registry for Parkinson’s Disease

    Final Number:
    672

    Authors:
    Jan Vesper; Roshini Jain; Heleen Scholtes; Alex Wang; Michael Barbe; Andrea Kuhn; Monika Potter-Nerger; Jens Volkmann; Steffen Paschen; Günther Deuschl

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Deep Brain Stimulation (DBS) systems have historically used ring-shaped electrodes that produce stimulation fields with limited control over field shape and volume of tissue activated. Directional current steering may permit a more personalized DBS approach with respect to individualized shape and pattern of electrical field and corresponding volume of tissue activated. Here we report initial real-world outcomes using a directional lead with a DBS system capable of multiple independent current source control (MICC) for use in managing symptoms of levodopa responsive Parkinson's disease (PD).

    Methods: The Vercise DBS Registry is a prospective, on-label, multi-center, international registry sponsored by Boston Scientific. Subjects in this cohort were implanted with a directional lead included as part of a multiple-source, constant-current directional DBS system (Vercise Cartesia, Boston Scientific). Subjects were followed up to 3 years post-implantation where their overall improvement in quality of life and PD motor symptoms was evaluated. Clinical endpoints evaluated at baseline and during study follow-up included Unified Parkinson's disease Rating Scale (UPDRS), MDS-UPDRS, Parkinson's disease Questionnaire (PDQ-39), and Global Impression of Change. Adverse events are also collected.

    Results: A total of over 100 subjects have been enrolled in this specific cohort. A 6.1 ± 12.11 (n = 73) point improvement was noted in the PDQ-39 Summary Index at the 6-month interval compared with Baseline and this improvement continued up to 1 year post-implant. Subjects, clinicians, and caregivers reported over 90% improvement in the symptoms at 6 months post-lead implant as compared with Baseline and this was maintained up to the 12-month interval. Additional data is to be presented.

    Conclusions: Enabling fractionalization of current using MICC can permit the application of a well-defined, shaped, electrical field. Use of a directional lead allows for the steering of current in horizontal directions by combining segmented leads and MICC.

    Patient Care: Using directional stimulation, it may be possible to achieve a bigger therapeutic window, thereby facilitating enhanced programming flexibility when optimizing for efficacy, while decreasing the likelihood of surpassing the adverse effect threshold.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) evaluate preliminary clinical outcomes in subjects implanted with a directional Lead 2) obtain insight regarding the potential advantage(s) of current steering using a directional lead as part of a directional DBS system.

    References: Steigerwald F. et al. Mov Disord. 2016 Aug;31(8):1240-3.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy